(NASDAQ: KALV) Kalvista Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Kalvista Pharmaceuticals's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast KALV's revenue for 2024 to be $752,639,201, with the lowest KALV revenue forecast at $752,639,201, and the highest KALV revenue forecast at $752,639,201. On average, 2 Wall Street analysts forecast KALV's revenue for 2025 to be $1,130,646,333, with the lowest KALV revenue forecast at $763,186,275, and the highest KALV revenue forecast at $1,498,106,391.
In 2026, KALV is forecast to generate $4,270,932,146 in revenue, with the lowest revenue forecast at $2,252,433,123 and the highest revenue forecast at $6,289,431,168.